P/E ratio for AstraZeneca (AZN)

P/E ratio history for AstraZeneca from 2001 to 2025

PE ratio at the end of each year

P/E ratio for similar companies or competitors

Company	P/E ratio	P/E ratio differencediff.	Country
Bristol-Myers Squibb BMY	17.1	-42.38%	🇺🇸 USA
Pfizer PFE	14.7	-50.24%	🇺🇸 USA
Merck MRK	12.8	-56.89%	🇺🇸 USA
GlaxoSmithKline GSK	13.1	-55.58%	🇬🇧 UK
Sanofi SNY	12.9	-56.39%	🇫🇷 France
Eli Lilly LLY	47.9	61.75%	🇺🇸 USA
Johnson & Johnson JNJ	19.2	-35.28%	🇺🇸 USA
Abbott Laboratories ABT	15.0	-49.15%	🇺🇸 USA
Biogen BIIB	16.0	-45.94%	🇺🇸 USA
Novartis NVS	17.8	-39.85%	🇨🇭 Switzerland

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.